HTG Molecular Diagnostics, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2017-12-27: Form 8-K; Period of report 2017-12-23; Description 8.01 Other Events; Details 8.01.
- 2017-12-26: Form 8-K; Period of report 2017-12-26; Description 8.01 Other Events; Details 8.01.
- 2017-12-20: Form 8-K; Period of report 2017-12-18; Description 8.01 Other Events; Details 8.01.
- 2017-11-07: Form 8-K; Period of report 2017-11-07; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2017-12-27 | 8-K | 2017-12-23 | 8.01 Other Events | 8.01 On December 23, 2017, HTG Molecular Diagnostics, Inc. (the “Company”) and Illumina, Inc. agreed to a third development plan under the parties’ Amended and Restated Development and Component Supply Agreement (the “Agreement”), effective dated May 31, 2017. | htgm-8k_20171223.htm |
| 2017-12-26 | 8-K | 2017-12-26 | 8.01 Other Events | 8.01 On December 26, 2017, we issued a press release announcing our entry into a new Master Collaboration Agreement for translational programs with Merck KGaA, Darmstadt, Germany. | htgm-8k_20171226.htm |
| 2017-12-20 | 8-K | 2017-12-18 | 8.01 Other Events | 8.01 On December 18, 2017, HTG Molecular Diagnostics, Inc. (the “Company”) and QIAGEN Manchester Limited (“QIAGEN”), a U.K. corporation and wholly owned subsidiary of QIAGEN N.V., amended the first statement of work (“SOW One”) under the Master Assay Development, Commercialization and Manufacturing Agreement (“Master Agreement”) between the parties. | htgm-8k_20171218.htm |
| 2017-11-07 | 8-K | 2017-11-07 | 2.02 Results of Operations and Financial Condition | 2.02 On November 7, 2017, HTG Molecular Diagnostics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2017. | htgm-8k_20171107.htm |
| 2017-11-01 | 8-K | 2017-10-26 | 8.01 Other Events | 8.01 On October 26, 2017, HTG Molecular Diagnostics, Inc. (the “Company”) entered into a second statement of work (“SOW Two”) with QIAGEN Manchester Limited (“QIAGEN”), a U.K. corporation and wholly owned subsidiary of QIAGEN N.V. SOW Two was entered into pursuant to the Company’s Master Assay Development, Commercialization and Manufacturing Agreement (the “Master Agreement”) with QIAGEN, and was made effective as of June 2, 2017 (“Onset Date”). | htgm-8k_20171026.htm |
| 2017-10-27 | 8-K | 2017-10-26 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; 3.02 Unregistered Sales of Equity Securities | 1.01 Entry into a Material Definitive Agreement. 2.03 The information contained under Item 1.01 of this report is incorporated under this Item 2.03 by reference. 3.02 The information contained under Item 1.01 of this report is incorporated under this Item 3.02 by reference. | htgm-8k_20171026.htm |
| 2017-09-20 | 8-K | 2017-09-20 | 8.01 Other Events | 8.01 On September 20, 2017, HTG Molecular Diagnostics, Inc. (the “Company” or “HTG”) announced in a press release that the United States Patent and Trademark Office has issued two U.S. Patents covering the Company’s technology and applications of its technology. | htgm-8k_20170920.htm |
| 2017-09-18 | 8-K | 2017-09-18 | 8.01 Other Events | 8.01 On September 18, 2017, HTG Molecular Diagnostics, Inc. (the “Company”) announced in a press release that it has successfully completed an audit of its Quality Management System for continued certification to ISO 13485. | htgm-8k_20170914.htm |
| 2017-09-11 | 8-K | 2017-09-11 | 8.01 Other Events | 8.01 On September 11, 2017, HTG Molecular Diagnostics, Inc. (the “Company”) announced in a press release that it expects to complete and file the fourth and final module related to the pre-market approval application (PMA) submission for its HTG EdgeSeq ALKPlus Assay in the second quarter of 2018. | htgm-8k_20170911.htm |
| 2017-08-21 | 8-K | 2017-08-15 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On August 15, 2017, HTG Molecular Diagnostics, Inc. (the “Company”) held its 2017 Annual Meeting of Stockholders (the “Annual Meeting”). | htgm-8k_20170815.htm |
| 2017-08-08 | 8-K | 2017-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2017, HTG Molecular Diagnostics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2017. | htgm-8k_20170630.htm |
| 2017-08-04 | 8-K | 2017-07-31 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 On July 31, 2017, HTG Molecular Diagnostics, Inc. (the “Company”) received written notice from the staff of the Nasdaq Stock Market LLC (“NASDAQ”) that, as of July 31, 2017, the Company was not in compliance with the market value of listed securities (“MVLS”) standard for continued listing set forth in NASDAQ Listing Rule 5550(b)(2), as the Company’s MVLS was below $35 million for the last 30 consecutive business days. | htgm-8k_20170731.htm |
| 2017-07-27 | 8-K | 2017-07-27 | 8.01 Other Events | 8.01 On July 27, 2017, HTG Molecular Diagnostics, Inc. (the “Company”) announced the initiation of its second development program with QIAGEN Manchester Limited (“QIAGEN”), a U.K. corporation and wholly owned subsidiary of QIAGEN N.V. under the companies’ Master Assay Development, Commercialization and Manufacturing Agreement (the “Master Agreement”). | htgm-8k_20170727.htm |
| 2017-06-14 | 8-K | 2017-06-14 | 8.01 Other Events | 8.01 Effective June 14, 2017, HTG Molecular Diagnostics, Inc. (the “Company”) entered into a statement of work (the “SOW”) with QIAGEN Manchester Limited (“QIAGEN”), a U.K. corporation and wholly owned subsidiary of QIAGEN N.V. The SOW was entered into pursuant to the Company’s Master Assay Development, Commercialization and Manufacturing Agreement (the “Master Agreement”) with QIAGEN, and addresses development activities expected to be conducted by the Company and QIAGEN in connection with the initial phase of a sponsor project agreement entered into between QIAGEN and a pharmaceutical company (“Initial Phase”). | htgm-8k_20170614.htm |
| 2017-06-02 | 8-K | 2017-06-02 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 As previously reported, on April 13, 2017 the Company entered into a Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., as sales agent (“Cantor Fitzgerald”), pursuant to which the Company may offer and sell, from time to time, through Cantor Fitzgerald, shares of the Company’s common stock, par value $0.001 per share, by any method deemed to be an “at the market offering” as defined in Rule 415 under the Securities Act of 1933, as amended (the “ATM Offering”). | d406446d8k.htm |
| 2017-06-01 | 8-K | 2017-05-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Our executive officers, including our principal executive officer, principal financial officer and our other named executive officers, are eligible to receive annual performance-based bonuses pursuant to their employment agreements with us. | htgm-8k_20170525.htm |
| 2017-05-15 | 8-K | 2017-05-15 | 2.02 Results of Operations and Financial Condition | 2.02 On May 15, 2017, HTG Molecular Diagnostics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2017. | htgm-8k_20170515.htm |
| 2017-05-04 | 8-K | 2017-05-04 | 8.01 Other Events | 8.01 On May 4, 2017, we announced in a press release that our new HTG EdgeSeq PATH Assay is expected to be available for research uses by the end of the second quarter of 2017. | htgm-8k_20170504.htm |
| 2017-04-24 | 8-K | 2017-04-24 | 8.01 Other Events | 8.01 On April 24, 2017, we announced in a press release that we have entered into a research collaboration agreement with Instituto Valenciano de Oncologia (IVO). | htgm-8k_20170424.htm |
| 2017-04-17 | 8-K | 2017-04-17 | 8.01 Other Events | 8.01 On April 17, 2017, we announced in a press release that we have entered into a master services agreement with Daiichi Sankyo Company, Limited (“Daiichi Sankyo”) for work to be performed in our VERI/O laboratory. | d380021d8k.htm |
| 2017-04-17 | 8-K | 2017-04-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On April 13, 2017, the Board of Directors (the “Board”) of HTG Molecular Diagnostics, Inc. (the “Company”) approved a performance-based retention and incentive bonus award (“Bonus Award”) for each of the Company’s Named Executive Officers in the amounts set forth in the table below. | d347578d8k.htm |
| 2017-04-13 | 8-K | 2017-04-13 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On April 12, 2017, The NASDAQ Stock Market LLC informed the Company that a NASDAQ Hearings Panel granted the Company’s request to transfer the listing of the Company’s common stock from The NASDAQ Global Market to The NASDAQ Capital Market, based on the Company’s compliance with all requirements for continued listing on The NASDAQ Capital Market. | d377009d8k.htm |
| 2017-03-28 | 8-K | 2017-03-28 | 7.01 Regulation FD Disclosure | 7.01 As previously announced, on March 23, 2017 HTG Molecular Diagnostics, Inc. (the “Company”) held a conference call to discuss the Company’s financial results for the fourth quarter and year ended December 31, 2016. | htgm-8k_20170323.htm |
| 2017-03-23 | 8-K | 2017-03-23 | 2.02 Results of Operations and Financial Condition | 2.02 On March 23, 2017, HTG Molecular Diagnostics, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2016. | htgm-8k_20170323.htm |
| 2017-03-07 | 8-K | 2017-03-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 1, 2017, Peter T. Bisgaard notified us of his decision to resign from our Board of Directors, effective March 2, 2017, citing time constraints resulting from other responsibilities. | htgm-8k_20170302.htm |
| 2017-02-21 | 8-K | 2017-02-14 | 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | 3.01 As previously reported, on August 15, 2016, HTG Molecular Diagnostics, Inc. (the “Company”) received notice from staff (the “Staff”) of the Nasdaq Stock Market LLC (“NASDAQ”) that the Company did not comply with the minimum $10,000,000 stockholders’ equity requirement for continued listing set forth in NASDAQ Listing Rule 5450(b)(1)(A) (the “Rule”). | htgm-8k_20170214.htm |